BeiGene (BGNE) News Today $194.56 +0.30 (+0.15%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Primecap Management Co. CA Lowers Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)Primecap Management Co. CA trimmed its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 0.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 4,974,289 shares of the company's stock after selling 12,000 shares during the period. Primecap ManNovember 21 at 7:15 AM | marketbeat.comBeiGene (NASDAQ:BGNE) Downgraded by StockNews.com to HoldNovember 21 at 5:37 AM | americanbankingnews.comStockNews.com Downgrades BeiGene (NASDAQ:BGNE) to HoldStockNews.com cut shares of BeiGene from a "buy" rating to a "hold" rating in a research note on Thursday.November 21 at 3:18 AM | marketbeat.comBeiGene settles litigation against generic filer of BrukinsaNovember 20 at 11:28 PM | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Has $50.71 Million Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 160.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 225,854 shares of the company's stock after purchasing an additional 138,97November 20 at 8:02 AM | marketbeat.comBeiGene legt Patentstreit bei und verlängert BRUKINSA-ExklusivitätNovember 19 at 11:14 AM | de.investing.comBeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSANovember 19 at 7:01 AM | businesswire.comLabcorp CFO Glenn Eisenberg Announces Plans to RetireNovember 19 at 7:00 AM | prnewswire.comLMR Partners LLP Takes Position in BeiGene, Ltd. (NASDAQ:BGNE)LMR Partners LLP bought a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,838 shares of the company's stock, valued at approximately $1,535,000. A numNovember 19 at 5:36 AM | marketbeat.comBeiGene Enters Oversold Territory (BGNE)November 18 at 12:02 AM | nasdaq.comBeiGene (NASDAQ:BGNE) Stock Price Expected to Rise, TD Cowen Analyst SaysNovember 17, 2024 | americanbankingnews.comFY2024 EPS Estimates for BeiGene Cut by Leerink PartnrsNovember 17, 2024 | americanbankingnews.comBeiGene: Balancing Promising Sales Growth with Operational Challenges – Hold Rating RecommendedNovember 16, 2024 | markets.businessinsider.comBeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy NowNovember 15, 2024 | msn.comBeiGene (NASDAQ:BGNE) Shares Gap Down - Here's WhyBeiGene (NASDAQ:BGNE) Shares Gap Down - What's Next?November 15, 2024 | marketbeat.comFY2024 EPS Estimates for BeiGene Decreased by AnalystBeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for BeiGene in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($5.98) per shareNovember 15, 2024 | marketbeat.comChina-Origin Drugmaker BeiGene to Rename Itself Amid Global PushNovember 15, 2024 | bloomberg.comOppenheimer Asset Management Inc. Buys 3,503 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Oppenheimer Asset Management Inc. raised its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,427 shares of the company's stockNovember 15, 2024 | marketbeat.comBeiGene gibt Finanzergebnisse für das dritte Quartal 2024 und Unternehmens-Updates bekanntNovember 15, 2024 | businesswire.comBeiGene-Aktien steigen nach Anhebung des Kursziels auf 260 US-Dollar von 254 US-DollarNovember 14, 2024 | de.investing.comBeiGene: Strong Buy Recommendation Driven by Impressive Sales Growth and Promising PipelineNovember 14, 2024 | markets.businessinsider.comBeiGene’s Strong Financial Performance and Growth Potential Justifies Buy RatingNovember 14, 2024 | markets.businessinsider.comLeerink Partnrs Has Negative View of BeiGene FY2025 EarningsBeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of BeiGene in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now forecasts that thNovember 14, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Short Interest UpdateBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 1,090,000 shares, a decline of 27.8% from the October 15th total of 1,510,000 shares. Based on an average trading volume of 319,500 shares, the short-interest ratio is presently 3.4 days.November 14, 2024 | marketbeat.comBeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against CancerNovember 14, 2024 | businesswire.comBeiGene (NASDAQ:BGNE) Issues Earnings ResultsBeiGene (NASDAQ:BGNE - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. BeiGene's revenue was up 28.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 EPS.November 13, 2024 | marketbeat.comBeiGene ADS: EPS übertrifft Schätzungen um 0,95 $ - Umsatz besser als erwartetNovember 13, 2024 | de.investing.comBeiGene-Aktien fallen trotz besser als erwarteter Q3-ErgebnisseNovember 13, 2024 | de.investing.comBaillie Gifford & Co. Acquires 23,807 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Baillie Gifford & Co. raised its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 0.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,705,756 shares of the company's stock after purchasing an additional 23,807 shNovember 12, 2024 | marketbeat.comBeiGene Announces Third Quarter 2024 Financial Results and Corporate UpdatesNovember 12, 2024 | businesswire.comBeiGene: Strong Revenue Outlook and Innovative Cancer Treatments Drive Buy RecommendationNovember 11, 2024 | markets.businessinsider.comXY Capital Ltd Takes Position in BeiGene, Ltd. (NASDAQ:BGNE)XY Capital Ltd acquired a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 30,464 shares of the company's stock, valued at approximately $November 9, 2024 | marketbeat.comAsset Management One Co. Ltd. Purchases 2,593 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Asset Management One Co. Ltd. boosted its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 14.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,453 shares of the company's stock afteNovember 9, 2024 | marketbeat.comBeiGene präsentiert innovatives Hämatologie-Portfolio für maligne B-Zell-Erkrankungen bei ASH 2024November 8, 2024 | businesswire.comBeiGene, Ltd. (NASDAQ:BGNE) Stake Cut by M&G PlcM&G Plc trimmed its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 3.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 173,075 shares of the company's stock after selling 6,704 shares during the quarter. M&G Plc owned approximately 0.18% of BeiNovember 7, 2024 | marketbeat.comVan ECK Associates Corp Sells 56,689 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Van ECK Associates Corp reduced its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 59.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,888 shares of the company's stock after selling 56,689 shares durinNovember 7, 2024 | marketbeat.comBeiGene to share new Brukinsa data at ASH Annual MeetingNovember 6, 2024 | markets.businessinsider.comBeiGene: TEVIMBRA European Push Continues With Positive CHMP OpinionNovember 6, 2024 | seekingalpha.comBeiGene to Present at the Jefferies London Healthcare ConferenceNovember 6, 2024 | businesswire.comBeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024November 5, 2024 | finance.yahoo.comAlphaCentric Advisors LLC Has $1.24 Million Stake in BeiGene, Ltd. (NASDAQ:BGNE)AlphaCentric Advisors LLC reduced its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 63.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,500 shares of the company's stock after selling 9,500 shares durinNovember 5, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has received an average rating of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1November 5, 2024 | marketbeat.comabrdn plc Sells 5,149 Shares of BeiGene, Ltd. (NASDAQ:BGNE)abrdn plc cut its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 15.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,919 shares of the company's stock after selling 5,149 shares during the quarter. abNovember 3, 2024 | marketbeat.comZymeworks drops as Wells Fargo cuts on valuationNovember 1, 2024 | msn.comLeerink Partnrs Has Bullish Estimate for BeiGene Q3 EarningsBeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Investment analysts at Leerink Partnrs upped their Q3 2024 earnings per share (EPS) estimates for shares of BeiGene in a note issued to investors on Monday, October 28th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($1.12) pOctober 30, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Acquires 3,486 Shares of BeiGene, Ltd. (NASDAQ:BGNE)China Universal Asset Management Co. Ltd. increased its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 69.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,510 shares of the company's stock after purchasing an additional 3,486 shares duOctober 29, 2024 | marketbeat.comBeiGene gibt Ableben des Vorstandsmitglieds Donald Glazer bekanntOctober 28, 2024 | de.investing.comBeiGene trauert um geliebtes Vorstandsmitglied Donald GlazerOctober 28, 2024 | businesswire.comBeiGene, Ltd.: BeiGene trauert um geliebtes Vorstandsmitglied Donald GlazerOctober 28, 2024 | finanznachrichten.deBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Down 24.1% in OctoberBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totalling 1,510,000 shares, a decrease of 24.1% from the September 30th total of 1,990,000 shares. Based on an average daily volume of 315,000 shares, the short-interest ratio is presently 4.8 days.October 27, 2024 | marketbeat.com Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention. Get your FREE, no-obligation Wealth Protection Guide now BGNE Media Mentions By Week BGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BGNE News Sentiment▼0.310.48▲Average Medical News Sentiment BGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BGNE Articles This Week▼276▲BGNE Articles Average Week Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BMRN News Today ALNY News Today GSK News Today TAK News Today BNTX News Today TEVA News Today VTRS News Today MRNA News Today SMMT News Today GMAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BGNE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeiGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
